Nurses' Notes
2045 — The client is a 68-year-old woman with type 2 diabetes and stage 3 chronic kidney disease. Her pneumonia is improving. She ate about 25 percent of dinner. Capillary glucose fell from 102 mg/dL at 1600 to 78 mg/dL at 2030. The 2100 medication administration record lists insulin degludec 24 units subcutaneously and insulin glargine 20 units subcutaneously as active. She denies sweating, tremor, palpitations, or confusion, is alert and oriented, has BP 126/72 mm Hg and HR 78/min, and states, "I use degludec at home, but I have never taken both long-acting insulins together."
Nurses' Notes
2045 — The client is a 68 歲女性 with type 2 diabetes and 第 3 期慢性腎臟病。她的肺炎正在改善。她晚餐約吃了 25%。血糖從 1600 時的 102 mg/dL 下降至 2030 時的 78 mg/dL。2100 的藥物給藥紀錄列出地特胰島素 (insulin degludec) 24 單位皮下注射和甘精胰島素 (insulin glargine) 20 單位皮下注射為作用中醫囑。她否認有出汗、顫抖、心悸或意識模糊，意識清楚且定向感良好，血壓為 126/72 mm Hg，心率 78 次/分，並表示："我平常在家使用地特胰島素，但我從未同時使用兩種長效胰島素。"